Skip to main content
. 2024 May 30;24:285. doi: 10.1186/s12872-024-03961-5

Fig. 3.

Fig. 3

Relative SGLT2i prescribing prevalence stratified by HF status. The relative percentages of canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin market share are depicted in the (A) HFrEF and (B) HFpEF cohorts regardless of T2DM status